During the past decade, Universitätsklinikum Ulm Zentrum für Innere Medizin conducted 14 clinical trials. In the 10-year time frame, 14 clinical trials started and 8 clinical trials were completed, i.e. on average, 57.1% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 4 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Universitätsklinikum Ulm Zentrum für Innere Medizin" #1 sponsor was "Galapagos NV" with 3 trials, followed by "Goethe University" with 3 trials sponsored, "Hoffmann-La Roche" with 3 trials sponsored, "AIO-Studien-gGmbH" with 2 trials sponsored and "Arrowhead Pharmaceuticals" with 2 trials sponsored. Other sponsors include 12 different institutions and companies that sponsored additional 19 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Universitätsklinikum Ulm Zentrum für Innere Medizin" #1 collaborator was "Gilead Sciences" with 3 trials as a collaborator, "Deutsche Krebshilfe e.V., Bonn (Germany)" with 2 trials as a collaborator, "ADIR, a Servier Group company" with 1 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator and "EMD Serono" with 1 trials as a collaborator. Other collaborators include 3 different institutions and companies that were collaborators in the rest 13 trials.

According to Clinical.Site data, the most researched conditions in "Universitätsklinikum Ulm Zentrum für Innere Medizin" are "Crohn's Disease" (5 trials), "Gastric Cancer" (2 trials), "Hepatitis B" (2 trials), "Ulcerative Colitis" (2 trials) and "Acute Lymphoblastic Leukemia" (1 trials). Many other conditions were trialed in "Universitätsklinikum Ulm Zentrum für Innere Medizin" in a lesser frequency.

Most popular intervention types in "Universitätsklinikum Ulm Zentrum für Innere Medizin" are "Drug" (28 trials), "Other" (2 trials), "Dietary Supplement" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (7 trials), "Filgotinib" (4 trials), "5-Fluorouracil" (2 trials), "Atezolizumab" (2 trials) and "Bevacizumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Universitätsklinikum Ulm Zentrum für Innere Medizin" are 30 trials for "All" genders.

Currently, there are NaN active trials in "Universitätsklinikum Ulm Zentrum für Innere Medizin". undefined are not yet recruiting, 4 are recruiting, 3 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 18 completed trials in Universitätsklinikum Ulm Zentrum für Innere Medizin, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Universitätsklinikum Ulm Zentrum für Innere Medizin, 6 "Phase 1" clinical trials were conducted, 14 "Phase 2" clinical trials and 11 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".